Glioblastoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• MGMT 20
• EGFR 14
• IDH 10
• STAT3 3
• TP53 0
• AKT 0
• mTOR 1
• PI3K 1
• PD-1 7
• ERK 0
• STING 0
• PD-L1 5
• YAP 0
• B7-H3 6
• MAPK 0
• PARP 1
• CTNNB1 0
• PTEN 1
• VEGF 5
• AMPK 0
• BRAF 1
• PRMT5 5
• TERT 3
• FGFR 1
• CDK4/6 0
• HDAC 0
• HIF-1 1
• IL-6 0
• NRF2 0
• PSMA 4
• MYC 2
• COX-2 0
• CXCR4 0
• EZH2 0
• CD47 0
• HER2 2
• JAK 0
• MEK 0
• MET 1
• METTL3 0
• TLR4 0
• ATM 2
• GPX4 0
• MDM2 0
• BCL-2 0
• CDKN2A 0
• CTLA-4 0
• FAK 0
• HSP90 0
• JNK 0
• MMP-9 1
• TNF 0
• CD19 0
• NF1 1
• NTRK 1
• TREM2 0
• ALK 2
• AR 0
• CD40 1
• HMGB1 0

15 of 15+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R21

  Tackling tumor recurrence in pediatric brain tumors: identification of epigenetic memory and tumor microenvironment conducive to tumor recurrence in an inducible and reversible H3K27M murine model.

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$401,115 awarded in fiscal year 2026· until Aug 2028

• NIH NINDS · R03

  Uncovering glycoRNA landscape in glioblastoma as a novel layer of immune evasion

  University of Texas Hlth Sci Ctr Houston· Houston, United States· US$78,000 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R42

  Targeting EGFR-Mutant NSCLC CNS Metastases with CM93, a Novel Brain-Penetrant EGFR Inhibitor

  Crimson Biopharm Inc· Brookline, United States· US$1,125,000 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · F31

  Co-engineering CAR T cells and CAR macrophages with synthetic cytokine signaling for glioblastoma immunotherapy

  Stanford University· Stanford, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NINDS · R21

  Regulation of Glioma Cell State Transition and Therapy Response by RNA Alternative Splicing

  Medical University of South Carolina· Charleston, United States· US$188,750 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of tRNA-dependent translational control in the onset and progression of Glioblastoma. (tRansGlio)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €226,421· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the mechanisms driving cancer cell DORMancy and REcurrence in glioblastoma (DORMIRE)

  Universite de Lausanne· Lausanne, Switzerland· EU contribution €292,119· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  ECLIPSE: Unveiling Brain Tumor Metabolism with Advanced In Vivo MRI

  Universitair Medisch Centrum Utrecht· Utrecht, Netherlands· EU contribution €2,099,257· until May 2032

• European Commission (Horizon Europe) · HORIZON-ERC

  Spatiotemporal Mapping of Immune Cell Behavior in Glioblastoma (VideoTranscriptomics)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €1,484,173· until Jan 2032

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Training Europe’s Future Leaders in AI-driven Neuro-Oncology Diagnostics and Discovery (FutureMIND)

  Ruprecht-Karls-Universitaet Heidelberg· Heidelberg, Germany· EU contribution €4,379,817· until Dec 2030· 8 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 828 running projects, newest first. Listed amounts together: US$405.9m + €179.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

  NCT06325683· National Cancer Institute (NCI)· Updated 12 Nov 2026

  “Scheduled Interim Monitoring”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

  NCT06325683· National Cancer Institute (NCI)· Source

• Surgical Nivolumab And Ipilimumab For Recurrent GBM

  NCT04606316· Gilbert Youssef· Source

• Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

  NCT07422363· National Cancer Institute (NCI)· Source

• Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

  NCT05743595· Washington University School of Medicine· Source

• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 93
• Organoids 33
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 12
• Gene Expression Profiling 151
• Sequence Analysis, RNA 10
• Exome Sequencing 2
• Proteomics 47
• Metabolomics 21
• Mass Spectrometry 9
• Flow Cytometry 16
• Immunohistochemistry 22
• Liquid Biopsy 10
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 226
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 234
• Machine Learning 266
• Deep Learning 43
• Cohort Studies 54
• Genome-Wide Association Study 13

• A Pan-Cancer Single-Cell Analysis of Intratumoral Copy-Number Diversity and Evolution.

  Cancer Discov, Nov 2026

• Reconstructing the single-cell spatiotemporal dynamics of glioblastoma invasion.

  Nat Commun, Nov 2026

• Advances in Single-Cell and Spatial Omics for Glioblastoma Precision Medicine.

  Curr Oncol Rep, Oct 2026

• Spatial heterogeneity in glioblastoma: linking single-cell and spatial multi-omics to vaccine immunotherapy.

  Front Immunol, Oct 2026

• Beyond M1 M2: single-cell insights into how glioblastoma reshapes tumour-associated macrophages.

  Front Immunol, Oct 2026

• Reduced Gene Module for Spatial Transcriptomics Recapitulates Single-Cell Molecular Classifications of Glioblastoma.

  Pathol Int, Oct 2026

• In Cellulo Observation of De Novo-Synthesized Nucleotide by Spectral Tracing of Glutamine-Derived Nitrogen Metabolism (QN-STIM) in Cancer Cells.

  Anal Chem, Sept 2026

• Multistage Genetic, Transcriptomic, and Single-Cell Evidence Prioritizes MAP1LC3A among Ferroptosis-Related Genes in Glioblastoma.

  J Vis Exp, Sept 2026

• Integration of Single-Cell and Bulk RNA Sequencing Data to Identify Lactylation-Related Gene Signatures in Hepatic Ischemia-Reperfusion Injury Using Machine Learning Algorithms.

  Int J Mol Sci, Sept 2026

• Single-cell Transcriptomic Characterization of DPP8 and DPP9 Expression Across Malignant Transcriptional States in Glioblastoma.

  J Pak Med Assoc, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.